Literature DB >> 1372801

Proteoglycan synthesis in human erythroleukaemia (HEL) cells.

B P Schick1, S Senkowski-Richardson.   

Abstract

Synthesis of sulphated proteoglycans was compared in human erythroleukaemia (HEL) cells grown under control conditions and under stimulation by dimethyl sulphoxide (DMSO) and phorbol 12-myristate 13-acetate (PMA). Synthesis of [35S]sulphate-labelled proteoglycans by DMSO-treated cells was decreased by about 35% relative to controls, but synthesis of proteoglycans by PMA-treated cells increased 3-4-fold. Control and DMSO-treated cells secreted 65% of the newly synthesized proteoglycans, but PMA-treated cells secreted more than 90%. Sepharose CL-6B chromatography and SDS/PAGE suggested the presence of several proteoglycans in the cells and culture medium. The PMA-treated cells synthesized a low-Mr proteoglycan (Kav. 0.3( that was not present in controls and DMSO-treated cultures. The proteoglycans of the cells and medium from control, DMSO-treated and PMA-treated cultures could be separated into three fractions by octyl-Sepharose chromatography. The proteoglycans were resistant to trypsin but were degraded by Pronase and papain to fragments similar in size to the NaOH/NaBH4-generated glycosaminoglycans. The average chain length of the glycosaminoglycans (Kav. 0.20 on Sepharose CL-6B for controls) was decreased by DMSO (Kav. 0.25) and by PMA (Kav. 0.30-0.38). Chondroitin ABC lyase digestion of the proteoglycans from the medium of the control cultures produced two core proteins at Mr 31,000 and 36,000. The DMSO medium proteoglycans had only the 31,000-Mr core protein, and the PMA culture medium proteoglycans had core proteins of Mr 27,000, 31,000 and 36,000. Changes in synthesis of proteoglycans induced by DMSO or PMA may have relevance for the maturation of haematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372801      PMCID: PMC1130837          DOI: 10.1042/bj2820651

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  61 in total

1.  Complete amino acid sequence of a human platelet proteoglycan.

Authors:  P M Alliel; J P Périn; P Maillet; F Bonnet; J P Rosa; P Jollès
Journal:  FEBS Lett       Date:  1988-08-15       Impact factor: 4.124

2.  Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates.

Authors:  H Saito; T Yamagata; S Suzuki
Journal:  J Biol Chem       Date:  1968-04-10       Impact factor: 5.157

3.  New method for quantitative determination of uronic acids.

Authors:  N Blumenkrantz; G Asboe-Hansen
Journal:  Anal Biochem       Date:  1973-08       Impact factor: 3.365

4.  Purification and analysis of the core protein of the protease-resistant intracellular chondroitin sulfate E proteoglycan from the interleukin 3-dependent mouse mast cell.

Authors:  R L Stevens; K Otsu; K F Austen
Journal:  J Biol Chem       Date:  1985-11-15       Impact factor: 5.157

5.  Specific release of proteoglycans from human natural killer cells during target lysis.

Authors:  R E Schmidt; R P MacDermott; G Bartley; M Bertovich; D A Amato; K F Austen; S F Schlossman; R L Stevens; J Ritz
Journal:  Nature       Date:  1985 Nov 21-27       Impact factor: 49.962

6.  Glycosaminoglycan metabolism of HL-60 cells during differentiation induction by tetradecanoylphorbol-13-acetate.

Authors:  S D Luikart; J L Sackrison
Journal:  Leuk Res       Date:  1986       Impact factor: 3.156

7.  Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages.

Authors:  L C Rosenberg; H U Choi; L H Tang; T L Johnson; S Pal; C Webber; A Reiner; A R Poole
Journal:  J Biol Chem       Date:  1985-05-25       Impact factor: 5.157

8.  Purification and characterization of human platelet proteoglycan.

Authors:  M Okayama; K Oguri; Y Fujiwara; H Nakanishi; H Yonekura; T Kondo; N Ui
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

9.  Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis.

Authors:  R P MacDermott; R E Schmidt; J P Caulfield; A Hein; G T Bartley; J Ritz; S F Schlossman; K F Austen; R L Stevens
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

10.  Invariant chain is the core protein of the Ia-associated chondroitin sulfate proteoglycan.

Authors:  A J Sant; S E Cullen; K S Giacoletto; B D Schwartz
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  5 in total

1.  Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.

Authors:  Anurag Purushothaman; Bryan P Toole
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

2.  Proteoglycan synthesis in human and murine haematopoietic progenitor cell lines: isolation and characterization of a heparan sulphate proteoglycan as a major proteoglycan from the human haematopoietic cell line TF-1.

Authors:  G Stöcker; Z Drzeniek; U Just; W Ostertag; B Siebertz; H Greiling; H D Haubeck
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

3.  Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice.

Authors:  Donna S Woulfe; Joanne Klimas Lilliendahl; Shelley August; Lubica Rauova; M Anna Kowalska; Magnus Abrink; Gunnar Pejler; James G White; Barbara P Schick
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

4.  Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Aristidis Moustakas; Kaisa E Happonen; Heidi Tveit; Kristian Prydz; Vassiliki T Labropoulou; Efstathia Giannopoulou; Haralambos P Kalofonos; Anna M Blom; Nikos K Karamanos; Achilleas D Theocharis
Journal:  PLoS One       Date:  2013-10-31       Impact factor: 3.240

Review 5.  Serglycin: at the crossroad of inflammation and malignancy.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Vassiliki T Labropoulou; Gianna Smirlaki; Argyrios Noulas; Nikos K Karamanos; Achilleas D Theocharis
Journal:  Front Oncol       Date:  2014-01-13       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.